Pictet Asset Management SA Has $3.73 Million Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Pictet Asset Management SA raised its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPNGet Rating) by 13.4% in the second quarter, HoldingsChannel.com reports. The fund owned 129,064 shares of the specialty pharmaceutical company’s stock after purchasing an additional 15,264 shares during the quarter. Pictet Asset Management SA’s holdings in Supernus Pharmaceuticals were worth $3,733,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in SUPN. First Horizon Advisors Inc. bought a new position in shares of Supernus Pharmaceuticals in the second quarter valued at about $34,000. Captrust Financial Advisors raised its position in shares of Supernus Pharmaceuticals by 163.3% in the first quarter. Captrust Financial Advisors now owns 2,983 shares of the specialty pharmaceutical company’s stock valued at $96,000 after purchasing an additional 1,850 shares during the period. Nisa Investment Advisors LLC raised its position in shares of Supernus Pharmaceuticals by 28.4% in the second quarter. Nisa Investment Advisors LLC now owns 3,390 shares of the specialty pharmaceutical company’s stock valued at $98,000 after purchasing an additional 750 shares during the period. Lazard Asset Management LLC raised its position in shares of Supernus Pharmaceuticals by 71.6% in the second quarter. Lazard Asset Management LLC now owns 3,498 shares of the specialty pharmaceutical company’s stock valued at $101,000 after purchasing an additional 1,460 shares during the period. Finally, Quent Capital LLC bought a new position in shares of Supernus Pharmaceuticals in the second quarter valued at about $116,000. Institutional investors and hedge funds own 99.81% of the company’s stock.

Insider Activity

In other news, VP Padmanabh P. Bhatt sold 6,800 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, November 11th. The shares were sold at an average price of $34.95, for a total value of $237,660.00. Following the completion of the sale, the vice president now directly owns 1,644 shares in the company, valued at $57,457.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, VP Padmanabh P. Bhatt sold 6,800 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, November 11th. The shares were sold at an average price of $34.95, for a total value of $237,660.00. Following the completion of the sale, the vice president now directly owns 1,644 shares in the company, valued at $57,457.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Jack A. Khattar sold 1,115 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Tuesday, November 15th. The shares were sold at an average price of $35.00, for a total transaction of $39,025.00. Following the completion of the sale, the chief executive officer now owns 780,742 shares of the company’s stock, valued at $27,325,970. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 8,615 shares of company stock worth $301,164. Corporate insiders own 7.99% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. StockNews.com raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, November 14th. Piper Sandler dropped their price objective on shares of Supernus Pharmaceuticals from $38.00 to $36.00 in a research note on Tuesday, October 11th.

Supernus Pharmaceuticals Trading Up 1.3 %

NASDAQ SUPN opened at $34.53 on Monday. Supernus Pharmaceuticals, Inc. has a 1-year low of $24.95 and a 1-year high of $36.08. The company has a 50 day moving average of $33.79 and a 200-day moving average of $31.38. The company has a market cap of $1.87 billion, a price-to-earnings ratio of 53.95 and a beta of 0.93.

About Supernus Pharmaceuticals

(Get Rating)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.

Featured Articles

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPNGet Rating).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.